The lesson from the past is simple. When we stop using vaccines that work, the diseases they prevent come back.

Read more on the state of viral hepatitis worldwide, where gaps in prevention, diagnosis, and treatment threaten 2030 targets.

Antivirals given for chronic hepatitis B include nucleos(t)ide analog monotherapy and pegylated interferon-alpha therapy, but ...

GSK (GSK.L) on Monday unveiled regulatory updates for its drug portfolio in China, with its asthma medication Exdensur approved and its chronic hepatitis B treatment bepirovirsen accepted for review.

Liver cancer is one of the world's deadliest cancers, and most cases are linked to chronic viral hepatitis. Yet scientists have lacked an animal model that faithfully recapitulates how the disease ...

Robert F. Kennedy Jr.’s sweeping changes to federal vaccine guidance are paused for now. But even if they’re reversed, ...

EMA accepts for review GSK’s MAA for bepirovirsen, an investigational ASO to treat adults with chronic hepatitis B: London, UK Saturday, March 28, 2026, 10:00 Hrs [IST] GSK plc ...

China NMPA accepts for review GSK’s NDA for bepirovirsen, an investigational ASO to treat adults with chronic hepatitis B: London, UK Tuesday, March 31, 2026, 16:00 Hrs [IST] GS ...

For decades, hepatitis C has been recognized as a major global public health challenge, with an estimated 58 million people ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Gilead Sciences Inc.